Healthcare Distribution Alliance – Patients Move Us.
Share Print


Marino-Blackburn Legislation Encourages DEA Collaboration and Transparency

February 19, 2014

ARLINGTON, Va. — HDMA President and CEO John M. Gray released the following statement on the introduction of legislation in the U.S. House of Representatives (The Ensuring Patient Access and Effective Drug Enforcement Act of 2014, H.R. 4069) to combat the inappropriate use of prescription medicines.

“The legislation introduced by Reps. Marino (R-Pa.) and Blackburn (R-Tenn.) will help foster greater collaboration, communication and transparency between industry stakeholders and regulators in our nation’s efforts to combat prescription drug abuse. Similar to the way drug manufacturers interact with the Food and Drug Administration, this bill will allow companies registered with the Drug Enforcement Administration (DEA) to submit corrective action plans to address DEA concerns, creating a more robust and transparent process to address drug diversion. This will hopefully curtail unnecessary supply chain disruptions that affect patient access to needed medications. Further, HDMA supports the creation of a Prescription Drug Abuse Working Group to encourage meaningful dialogue and coordination between supply chain stakeholders and federal regulators. Finally, by clarifying key terminology in the Controlled Substances Act, registrants will have a better understanding of their responsibilities under the law.

“Prescription drug abuse is a serious and complex public health challenge, and while there is no ‘silver bullet’ to eradicating this problem, this legislation would go a long way in fostering a collaborative effort to minimize supply chain disruptions and ensure that legitimate patients are able to access the medicines they need. HDMA and its primary healthcare distributor members are committed to being part of the solution, working hand-in-hand with our supply chain partners and government officials to find ways to slow this epidemic. We commend Reps. Marino and Blackburn for their leadership on this issue and look forward to working with all stakeholders in support of this legislation.”


The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.


Website design and development by, inc
© 2018 Healthcare Distribution Alliance. All rights reserved.
HDA: M | C | D | NF | O365